Navigation Links
Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain
Date:8/13/2009

BRISTOL, Tenn., Aug. 13 /PRNewswire-FirstCall/ -- King Pharmaceuticals((R)), Inc. (NYSE: KG) today announced that the U.S. Food and Drug Administration (FDA) has approved EMBEDA(TM) (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules for oral use, a long-acting Schedule II opioid analgesic for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. EMBEDA(TM) is the first FDA-approved long-acting opioid that is designed to reduce drug liking and euphoria when tampered with by crushing or chewing.

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/embeda/39189/

"Today's approval of EMBEDA(TM) marks a milestone in pain care, and King is proud to bring this new technology to the U.S. market," said Brian A. Markison, Chairman, President, and Chief Executive Officer of King. "King is committed to providing resources and medicines to patients and healthcare professionals to achieve optimal pain control. We are focused on developing medicines that use novel technologies designed to reduce drug liking and make it more difficult to extract the active ingredient. We anticipate a September 2009 launch for EMBEDA(TM)."

Utilizing King's proprietary technology, EMBEDA(TM) contains extended-release morphine pellets, each with an inner core of naltrexone hydrochloride, an opioid receptor antagonist. If taken as directed, the morphine relieves pain while the sequestered naltrexone hydrochloride passes through the body with no intended clinical effect. If EMBEDA(TM) is crushed or chewed, the naltrexone is released and absorbed with the morphine, r
'/>"/>

SOURCE King Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Video: Nutrition Comes to NASCAR
2. Video: Circulatory Care of New Jersey
3. Video: GEN Video Hits Home with Web Audience
4. Video: Beyond the Red Door: Gildas Club Worldwide and DKNY Host Successful Benefit Event
5. Video: Food Expert B. Smith to Provide Healthy Menu Makeovers
6. Video: New FDA-Approved Sun Protectant Saves Skin All Year Round
7. Video: Kyphon Supports World Osteoporosis Day on October 20, 2007 to Raise Awareness of Osteoporosis and Spinal Fracture Risk
8. Video: Trinity Mother Frances Neurosurgeon First in Region to Remove Brain Tumor Using Unique Surgical Procedure
9. Video: Holiday Safety Is Important
10. Video: Grin Big With an Award-Winning Smile
11. Video: BSP Pharma Inc. Announces Groundbreaking Findings from The Australian Centre for Complementary Medicine Education and Research Joint Health Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... ... 27, 2015 , ... The heroin epidemic is affecting the Charlotte in North ... 7th. The rate for heroin usage has continued to climb around the country in ... less expensive alternative for those with an addiction to prescription opiate medications. According to ...
(Date:7/27/2015)... ... , ... On July 14, 2015, Harper’s Bazaar Magazine in an article titled ... such as stretch marks , fine lines , and acne scars ... listed include lasers, ultrasound, radio frequency, Botox, and dermal fillers. It is pointed out ...
(Date:7/27/2015)... ... July 27, 2015 , ... The Maricopa Community Colleges ... of the foster care system to get into and complete college. , The ... introduced at an event today with partners from across the valley. , The initiative ...
(Date:7/27/2015)... ... July 27, 2015 , ... ... Calcium Propionate industry is a professional and in-depth research report. The report ... chain structure, international market analysis etc. This report covers the global (US, ...
(Date:7/27/2015)... , ... July 27, 2015 , ... Throughout its 20 ... premier doctors and medical providers working on a lien basis. As the personal ... wide range of providers from chiropractors, to orthopedists, to pain management physicians, to psychologists ...
Breaking Medicine News(10 mins):Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 2Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 3Health News:The Latest Treatment Options for Seven Common Skin Issues 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 3Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 3Health News:Doctors on Liens Adds Highly Respected Physical Therapy Office in Los Angeles 2
... Sept. 9 As the nation awaits President Obama,s address ... The Philanthropic Collaborative (TPC) sent today a letter to the ... community foundations in the field of health. , , ... in the social and economic effectiveness of health-related philanthropic activities. ...
... that the sexual transmitted infection known as Trichomonas ... prostate cancer in a study published online September 9 ... . Jennifer Rider Stark, ScD, of the department ... in Boston, and colleagues conducted a case-control study nested ...
... , , , WASHINGTON, Sept. ... guest of President Barack Obama tonight for the President,s historic speech ... nation. , , As Co-Chair of the ... spearheading a bold campaign encouraging mayors around the country to urge ...
... Imaging technology might advance treatment of psychotic disorders, researchers ... technology has helped researchers pinpoint the part of the ... as schizophrenia begin, a new study says. , The ... in their early stages and help scientists develop more ...
... Republican Congressman Slated to Oppose President Obama,s Health Care Plan ... , , WASHINGTON, Sept. 9 Public ... Charles Boustany (R-La.) and the expected opposing remarks he will deliver ... session of Congress on health care reform. , , ...
... , , , KEYSTONE TREATMENT AND ... SIMILAR EVENTS TO FOLLOW AT CANTON AT 1 PM: , ... Media welcome at both locations , , SIOUX ... Sioux Falls, S.D. will be the 2009 national headquarters at 11 AM Wednesday, ...
Cached Medicine News:Health News:In Letter to President, TPC Highlights Foundation Grants in Health 2Health News:In Letter to President, TPC Highlights Foundation Grants in Health 3Health News:JNCI news brief: STD confirmed to be associated with increased risk of prostate cancer 2Health News:Mayor Gavin Newsom to Be President Obama's Guest for Healthcare Reform Speech to the Nation 2Health News:Brain Scans Could Help Spot Schizophrenia Earlier 2Health News:Rep. Boustany Hauled in $1.25 Million From Health and Insurance Industry 2Health News:Wed., Sept. 16, 11 AM News Conference: Sioux Falls' Keystone Treatment Center Is National HQ to Lead 100 Locations Nationwide in Balloon Liftoff Celebrating Recovery Against New Wave of Drug Abuse; Former U.S. Drug Czar/4-Star Gen. Barry McCaffrey, Lieute 2
(Date:7/27/2015)... and MENLO PARK, Calif. , ... (OTCQX: DMPI) ("DelMar" and the "Company"), a ... cancer therapies in new orphan drug indications, today ... and accredited investors for a registered direct placement ... and 3.35 million common stock purchase warrants for ...
(Date:7/27/2015)... --  DocResponse was ranked the most accurate ... peer-reviewed study , "Evaluation of symptom checkers for ... the July issue of The British Medical Journal ... researchers determined that performance of online symptom checkers ... first in standardized patient evaluations more often than ...
(Date:7/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/7lz2fk/intraoperative ) has ... by Type (Intraoperative CT, Intraoperative MRI, Intraoperative Ultrasound) , ... Forecast to 2019" report to their offering. ... value of $2.1 Billion by 2019 from $1.8 Billion ... forecast period. The intraoperative imaging market ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 2DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 3Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 3Global Intraoperative Imaging (Intraoperative CT, Intraoperative MRI, Intraoperative Ultrasound) Market Forecasts & Trends 2015-2019 2
... 17, 2012  Boston Scientific Corporation (NYSE: BSX ... market launch of the Epic™ Vascular Self-Expanding Stent System.  ... in patients with iliac artery stenosis, a form of ... by insufficient blood flow.  "The Epic ...
... RARITAN, N.J., May 17, 2012 Janssen Pharmaceuticals, ... Phase 3 study suggesting NUCYNTA® ER (tapentadol) extended-release ... providing pain management among adults with chronic moderate ... of the study were presented at the 31st ...
Cached Medicine Technology:Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent 2Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent 3Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent 4Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent 5Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 2Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 3Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 4Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 5Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 6Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 7Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 8Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 9Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 10Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 11Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 12
... The REFLEXION 1st MPJ IMPLANT SYSTEM ... the primary reconstruction of the 1st metatarsal ... traumatic arthritis or revision of a previous ... achieve three goals: pain relief, superior function ...
... The hands play an important part in ... impairments and rheumatic changes can cause severe ... of the finger-joint prostheses was to produce ... the natural function as nearly possible.,The cementless ...
... The OSTEOMED 3.0/4.0mm CANNULATED SCREW SYSTEM ... Orthopedic Hand surgeon and Podiatrist, can be ... fusions. The system features two simplified ... Both screw sizes utilize one unique set ...
... the lower extremity for prepping before hip or ... procedures and particularly helpful for supporting the leg ... By holding the foot/ankle in an externally rotated ... which helps eliminate the need for manual support.,The ...
Medicine Products: